Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can UV light beat Drug-Resistant ringworm?

NCT ID NCT07242703

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether narrow-band ultraviolet B (NB-UVB) light therapy can help people with ringworm infections that don't get better with standard antifungal drugs. The trial will enroll 36 adults who have had at least two relapses in the past six months. Half will receive UVB light alone, and the other half will continue standard antifungal treatment. Researchers will measure how well the infection clears and whether it stays away.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
narrow-band ultraviolet B (NB-UVB) phototherapy
What this could lead to
If it works, this could offer a new treatment option for people with ringworm that keeps coming back or doesn't respond to standard antifungal pills.
What could go wrong
This is a very small, early-stage trial with only 36 people. It's not yet recruiting, so results are far off. UVB light can cause skin burns or increase skin cancer risk with long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years. Both sexes. Clinical diagnosis of tinea corporis or cruris. Failure of ≥4 weeks of systemic antifungal therapy (e.g., terbinafine or itraconazole). No antifungal (topical or systemic) or corticosteroid treatment in the 2 weeks preceding enrollment. Recurrent infection (≥2 relapses in the past 6 months) Positive KOH microscopy and culture at baseline Exclusion Criteria: * Photosensitivity disorders or photosensitizing medications. Xeroderma pigmentosa, LE or other photosensitive dermatoses. dermatomyositis. Other skin conditions (psoriasis, eczema, etc.). Known autoimmune diseases, immunosuppression, or coagulopathies..

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fungal resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dermatophytosis of groin and perianal area tinea corporis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fungal resistance

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.